MNOV (Medicinova, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by MNOV officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-25 | Hideki Nagao | Director | A | — | — |
| 2026-06-25 | CAROLYN BEAVER | Director | A | — | — |
| 2026-06-25 | Nicole Lemerond | Director | A | — | — |
| 2026-01-20 | YUICHI IWAKI | President and CEO | A | — | — |
| 2026-01-20 | Kazuko Matsuda | Chief Medical Officer | A | — | — |
| 2025-06-20 | Nicole Lemerond | Director | A | — | — |
| 2025-06-20 | Hideki Nagao | Director | A | — | — |
| 2025-06-20 | CAROLYN BEAVER | Director | A | — | — |
| 2025-02-14 | Hideki Nagao | Director | A | — | — |
| 2025-02-14 | YUICHI IWAKI | President and CEO | A | — | — |
| 2025-02-14 | Nicole Lemerond | Director | A | — | — |
| 2025-02-14 | Kazuko Matsuda | Chief Medical Officer | A | — | — |
| 2025-02-14 | CAROLYN BEAVER | Director | A | — | — |
| 2025-01-10 | Kazuko Matsuda | Chief Medical Officer | A | — | — |
| 2025-01-10 | YUICHI IWAKI | President and CEO | A | — | — |
| 2024-06-12 | Hideki Nagao | Director | A | — | — |
| 2024-06-12 | Nicole Lemerond | Director | A | — | — |
| 2024-06-12 | CAROLYN BEAVER | Director | A | — | — |
| 2024-01-11 | Geoffrey OBrien | Vice President | A | — | — |
| 2024-01-11 | Kazuko Matsuda | Chief Medical Officer | A | — | — |
| 2024-01-11 | YUICHI IWAKI | President and CEO | A | — | — |
| 2023-08-08 | Nicole Lemerond | Director | A | — | — |
| 2023-06-15 | Hideki Nagao | Director | A | — | — |
| 2023-06-15 | CAROLYN BEAVER | Director | A | — | — |
| 2023-01-25 | YUICHI IWAKI | President and CEO | A | — | — |
| 2023-01-25 | Kazuko Matsuda | Chief Medical Officer | A | — | — |
| 2023-01-25 | Geoffrey OBrien | Vice President | A | — | — |
| 2022-11-30 | Hideki Nagao | Director | Sell | — | — |
| 2022-11-23 | Hideki Nagao | Director | Sell | — | — |
| 2022-11-21 | Hideki Nagao | Director | Sell | — | — |
| 2022-06-17 | Hideki Nagao | Director | A | — | — |
| 2022-06-17 | CAROLYN BEAVER | Director | A | — | — |
| 2022-01-31 | Kazuko Matsuda | Chief Medical Officer | A | — | — |
| 2022-01-31 | Geoffrey OBrien | Vice President | A | — | — |
| 2022-01-31 | YUICHI IWAKI | President and CEO | A | — | — |
| 2021-08-25 | Kazuko Matsuda | Chief Medical Officer | M | — | — |
| 2021-07-23 | YUICHI IWAKI | President and CEO | M | — | — |
| 2021-06-28 | Kazuko Matsuda | Chief Medical Officer | M | — | — |
| 2021-06-21 | CAROLYN BEAVER | Director | A | — | — |
| 2021-06-21 | Hideki Nagao | Director | A | — | — |
| 2021-05-20 | Geoffrey OBrien | Vice President | M | — | — |
| 2021-04-26 | Federico C.A. Gaeta | Chief Scientific Officer | A | — | — |
| 2021-03-15 | Hideki Nagao | Director | Sell | — | — |
| 2021-03-01 | YUICHI IWAKI | President and CEO | M | — | — |
| 2021-02-04 | Kazuko Matsuda | Chief Medical Officer | A | — | — |
| 2021-02-04 | Geoffrey OBrien | Vice President | A | — | — |
| 2021-02-04 | YUICHI IWAKI | President and CEO | A | — | — |
| 2020-10-22 | CAROLYN BEAVER | Director | A | — | — |
| 2020-09-16 | Hideki Nagao | Director | Sell | — | — |
| 2020-08-07 | Hideki Nagao | Director | M | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 1,091,933 | — |
| — | VP and Head of Japanese Office | 935,530 | — |
| — | Director | 759,700 | — |
| — | Chief Medical Officer | 322,996 | — |
| — | Director | 106,800 | — |
| — | Vice President | 48,318 | — |
| — | Director | 45,000 | — |
| — | Chief Medical Officer | 31,744 | — |
| — | Director | 15,000 | — |
| — | Director | 5,000 | — |
| — | Chief Business Officer | 4,000 | — |
| — | Chief Scientific Officer | 1,700 | — |
| — | Director | 1,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MNOV quote page; the site-wide leaderboard is on the insider transactions hub.